Alchemia Still A Buy Despite Delays

Even possible delays can’t stop ABN Amro Morgan from remaining optimistic on the prospects of biotech play Alchemia (ACL), the broker retaining its Buy rating and $1.06 price target on the stock even though the company’s recent dealings with the Food & Drug Administration in the US are resulting in a lengthening of time lines for its product coming to market.

Read More

Analyst Views